keyword
https://read.qxmd.com/read/38616015/mesenchymal-stem-cell-transplantation-may-be-able-to-induce-immunological-tolerance-in-systemic-lupus-erythematosus
#21
JOURNAL ARTICLE
Julia Barbado
Systemic lupus erythematosus (SLE) is a common, potentially fatal autoimmune disease involving a significant inflammatory response. SLE is characterised by failure of self-tolerance and activation of autoreactive lymphocytes, leading to persistent disease. Although current treatments achieve some improvement in patients, some SLE patients are refractory and others relapse after drug withdrawal. The toxicity of current drug regimens, with recurrent infections, together with ongoing inflammation, contribute significantly to the progressive decline in organ function...
April 12, 2024: Biomedical Journal
https://read.qxmd.com/read/38615184/improved-long-term-survival-rate-in-the-responders-to-bortezomib-cyclophosphamide-dexamethasone-induction-therapy-in-a-transplant-eligible-cohort-of-predominantly-middle-age-multiple-myeloma-patients
#22
JOURNAL ARTICLE
Ahmed Kotb Abdrabou, Fahad Al Sharif, Riad El Fakih, Hazaa Al Zahrani, Ruah Al Yamany, Mostafa Saleh, Saud Alhayli, Zakia Al Somali, Ahmad Alotaibi, AlFadel AlShaibani, Farah Deeba, Maryam Asif, Syed Ahmed Osman Ali Ahmed, Feras Al Fraih, Marwan Shaheen, Ali Alahmari, Walid Rasheed, Naeem Arshad Chaudhri, Fahad Al Mohareb, Mahmoud Aljurf, Amr Hanbali
BACKGROUND: Multiple myeloma (MM) represents the second most common hematologic malignancy (15%). Induction with bortezomib, cyclophosphamide, and dexamthasone VCd (d: low dose dexamthasone) regimen is widely used due to its high effectiveness, low toxicity and good tolerability, particularly with renal impairment. Real-world data on the use of VCD in clinical practice is lacking. OBJECTIVES: Evaluate the real-world experience of the VCD regimen. DESIGN: Retrospective...
2024: Annals of Saudi Medicine
https://read.qxmd.com/read/38613816/low-initial-cell-density-promotes-the-differentiation-and-maturation-of-human-pluripotent-stem-cells-into-erythrocytes
#23
JOURNAL ARTICLE
Liqing Liang, Lei Xu, Qian Dong, Jing Zhang, Mingyi Qu, Xin Yuan, Quan Zeng, Huilin Li, Bowen Zhang, Chao Wang, Tao Fan, Li-Juan He, Wen Yue, Xiaoyan Xie, Xuetao Pei
Human pluripotent stem cell (hPSC)-derived red blood cells (RBCs) possess great potential for compensating shortages in transfusion medicine. For better RBC generation from hPSCs, we compared the cell seeding density in the embryoid body formation-based hPSC induction protocol. In the selection of low- and high-density inoculation conditions, we found that low-density culture performed better in the final RBC product with more cell output and increased average cellular hemoglobin content. An elaborate study using flow cytometry demonstrated that low inoculation density promoted endothelial-to-hematopoietic transition, followed by improved hematopoietic progenitor formation and erythrocyte generation...
April 13, 2024: Stem Cells and Development
https://read.qxmd.com/read/38611035/using-targeted-transcriptome-and-machine-learning-of-pre-and-post-transplant-bone-marrow-samples-to-predict-acute-graft-versus-host-disease-and-overall-survival-after-allogeneic-stem-cell-transplantation
#24
JOURNAL ARTICLE
Scott D Rowley, Thomas S Gunning, Michael Pelliccia, Alexandra Della Pia, Albert Lee, James Behrmann, Ayrton Bangolo, Parul Jandir, Hong Zhang, Sukhdeep Kaur, Hyung C Suh, Michele Donato, Maher Albitar, Andrew Ip
Acute graft-versus-host disease (aGvHD) remains a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). We performed RNA analysis of 1408 candidate genes in bone marrow samples obtained from 167 patients undergoing HSCT. RNA expression data were used in a machine learning algorithm to predict the presence or absence of aGvHD using either random forest or extreme gradient boosting algorithms. Patients were randomly divided into training (2/3 of patients) and validation (1/3 of patients) sets...
March 29, 2024: Cancers
https://read.qxmd.com/read/38610812/venetoclax-combination-treatment-of-acute-myeloid-leukemia-in-adolescents-and-young-adult-patients
#25
REVIEW
Elena Chatzikalil, Kleoniki Roka, Panagiotis T Diamantopoulos, Efthymia Rigatou, Georgia Avgerinou, Antonis Kattamis, Elena E Solomou
Over the past two decades, the prognosis in adolescents and young adults (AYAs) diagnosed with acute myeloid leukemia (AML) has significantly improved. The standard intensive cytotoxic treatment approach for AYAs with AML, consisting of induction chemotherapy with anthracycline/cytarabine combination followed by consolidation chemotherapy or stem cell transplantation, has lately been shifting toward novel targeted therapies, mostly in the fields of clinical trials. One of the most recent advances in treating AML is the combination of the B-cell lymphoma 2 (Bcl-2) inhibitor venetoclax with hypomethylating agents, which has been studied in elderly populations and was approved by the Food and Drug Administration (FDA) for patients over 75 years of age or patients excluded from intensive chemotherapy induction schemas due to comorbidities...
April 1, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38609727/therapeutic-progress-in-relapsed-refractory-multiple-myeloma
#26
REVIEW
Qi Chen, Min Zhang, Shan Zheng, Yuxin Tong, Yamin Tan
Improvement in the therapeutics for multiple myeloma (MM) has been continuously developed owing to the application of novel drugs and technologies in the last 20 years. The standard first-line therapy for MM consists of a three-drug induction regimen based on immunomodulatory drugs and proteasome inhibitors combined with autologous stem cell transplantation. However, MM remains incurable; therefore, therapies for relapsed/refractory MM (RRMM) are emerging and evolving rapidly. This study aimed to summarize and review the results of RRMM trials over the past 5 years to provide a holistic overview and insights for practitioners in related fields and to provide additional ideas for clinical trialists...
April 13, 2024: Annals of Hematology
https://read.qxmd.com/read/38609316/phase-1-study-combining-elotuzumab-with-autologous-stem-cell-transplant-and-lenalidomide-for-multiple-myeloma
#27
JOURNAL ARTICLE
David G Coffey, Keren Osman, Adolfo Aleman, Selma Bekri, Simone Kats, Amishi Dhadwal, Donna Catamero, Seunghee Kim-Schulze, Sacha Gnjatic, Ajai Chari, Samir Parekh, Sundar Jagannath, Hearn Jay Cho
BACKGROUND: Autologous stem cell transplantation (ASCT) after induction therapy improves disease-free survival for patients with multiple myeloma (MM). While the goal of ASCT is to render a minimal disease state, it is also associated with eradication of immunosuppressive cells, and we hypothesize that early introduction of immunotherapy post-ASCT may provide a window of opportunity to boost treatment efficacy. METHODS: We conducted a phase 1 clinical trial to investigate the application of autologous lymphocyte infusion and anti-SLAMF7 monoclonal antibody, elotuzumab, after ASCT in patients with newly diagnosed MM previously treated with induction therapy...
April 12, 2024: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/38606862/bisphenol-analogs-downregulate-the-self-renewal-potential-of-spermatogonial-stem-cells
#28
JOURNAL ARTICLE
Seo-Hee Kim, Seung Hee Shin, Seok-Man Kim, Sang-Eun Jung, Beom-Jin Shin, Jin Seop Ahn, Kyoung Taek Lim, Dong-Hwan Kim, Kichoon Lee, Buom-Yong Ryu
PURPOSE: In this study, we investigated the effect of bisphenol-A (BPA) and its major analogs, bisphenol-F (BPF), and bisphenol-S (BPS), on spermatogonial stem cells (SSCs) populations using in vitro SSC culture and in vivo transplantation models. MATERIALS AND METHODS: SSCs enriched from 6- to 8-day-old C57BL/6-eGFP+ male mice testes were treated with varying concentrations of bisphenols for 7 days to examine bisphenol-derived cytotoxicity and changes in SSC characteristics...
March 28, 2024: World Journal of Men's Health
https://read.qxmd.com/read/38605231/upfront-allogeneic-hematopoietic-stem-cell-transplantation-for-adult-t-cell-acute-lymphoblastic-leukemia-lymphoma-in-first-complete-remission-a-single-center-study
#29
JOURNAL ARTICLE
Zhenyang Gu, Fei Li, Meng Li, Lu Wang, Ning Lu, Xiangshu Jin, Lili Wang, Chunji Gao, Liping Dou, Daihong Liu
BACKGROUND: Real-world data on outcomes of upfront allogeneic hematopoietic stem cell transplantation (allo-HCT) for adult T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) patients in first complete remission (CR1) is still lacking. METHODS: A single center retrospective study was conducted from 94 consecutive patients received their first allo-HCT between 2010 and 2021, which include 76 patients received upfront allo-HCT and 18 patients received allo-HCT in non-upfront settings...
April 12, 2024: Annals of Hematology
https://read.qxmd.com/read/38603944/acute-rejection-rates-in-vascularized-composite-allografts-a-systematic-review-of-case-reports
#30
REVIEW
Loïc Van Dieren, Pierre Tawa, Marie Coppens, Laura Naenen, Omer Dogan, Tom Quisenaerts, Hyshem H Lancia, Haïzam Oubari, Yohann Dabi, Maxime De Fré, Filip Thiessen Ef, Curtis L Cetrulo, Alexandre G Lellouch
INTRODUCTION: Vascularized Composite Allografts (VCA) are usually performed in a full major histocompatibility complex mismatch setting, with a risk of acute rejection depending on factors such as the type of immunosuppression therapy and the quality of graft preservation. In this systematic review, we present the different immunosuppression protocols used in VCA and point out relationships between acute rejection rates and possible factors that might influence it. METHODS: This systematic review was performed according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines...
April 10, 2024: Journal of Surgical Research
https://read.qxmd.com/read/38603646/mitoxantrone-versus-liposomal-daunorubicin-in-induction-of-pediatric-aml-with-risk-stratification-based-on-flow-cytometry-measurement-of-residual-disease
#31
JOURNAL ARTICLE
Anne Tierens, Nira Arad-Cohen, Daniel Cheuk, Barbara De Moerloose, Jose Maria Fernandez Navarro, Henrik Hasle, Kirsi Jahnukainen, Kristian Løvvik Juul-Dam, Gertjan Kaspers, Zanna Kovalova, Birgitte Lausen, Ulrika Norén-Nyström, Josefine Palle, Ramune Pasauliene, Cornelis Jan Pronk, Kadri Saks, Bernward Zeller, Jonas Abrahamsson
PURPOSE: Measurable residual disease (MRD) by using flow cytometry after induction therapy is strongly prognostic in pediatric AML, and hematopoietic stem-cell transplant (hSCT) may counteract a poor response. We designed a phase III study with intensified response-guided induction and MRD-based risk stratification and treated poor induction response with hSCT. The efficacy of liposomal daunorubicin (DNX) in induction was compared with mitoxantrone. METHODS: The study planned to randomly assign 300 patients, but the production of DNX ceased in 2017...
April 11, 2024: Journal of Clinical Oncology
https://read.qxmd.com/read/38599892/updates-in-induction-immunosuppression-regimens-for-intestinal-transplantation
#32
REVIEW
Johann Paulo Guzman, Mohamed Maklad, Mohammed Osman, Ayat Elsherif, Masato Fujiki
Intestinal allografts are the most immunologically complex and carry the highest risk of rejection among solid organ transplantation, necessitating complex immunosuppressive management. We evaluated the latest information regarding induction immunosuppression, with an emphasis on established, novel, and emergent therapies. We also reviewed classic and novel induction immunosuppression strategies for highly sensitized recipients. Comparable progress has been made in intestinal transplantation clinical outcomes since the implementation of induction strategies...
April 9, 2024: Human Immunology
https://read.qxmd.com/read/38598710/myeloablative-vs-non-myeloablative-consolidation-for-primary-central-nervous-system-lymphoma-results-of-alliance-51101
#33
JOURNAL ARTICLE
Tracy T Batchelor, Sharmila Giri, Amy S Ruppert, Susan Geyer, Scott E Smith, Nimish Mohile, Lode J Swinnen, Jonathan W Friedberg, Brad S Kahl, Nancy L Bartlett, Eric D Hsi, Bruce David Cheson, Nina D Wagner-Johnston, Lakshmi Nayak, John P Leonard, James Louis Rubenstein
While it is evident that standard dose whole brain radiotherapy as consolidation is associated with significant neurotoxicity, the optimal consolidative strategy for primary central nervous system lymphoma (PCNSL) is not defined. We performed a randomized phase 2 clinical trial via the U.S. Alliance cancer cooperative group to compare myeloablative consolidation supported by autologous stem cell transplantation with non-myeloablative consolidation after induction therapy for PCNSL. This is the first randomized trial to be initiated that eliminates whole brain radiotherapy as a consolidative approach in newly-diagnosed PCNSL...
April 10, 2024: Blood Advances
https://read.qxmd.com/read/38597972/bioengineered-msc-cxcr2-transdifferentiated-keratinocyte-like-cell-derived-organoid-potentiates-skin-regeneration-through-erk1-2-and-stat3-signaling-in-diabetic-wound
#34
JOURNAL ARTICLE
Subholakshmi Choudhury, Neha R Dhoke, Shilpa Chawla, Amitava Das
Skin regeneration is severely compromised in diabetic foot ulcers. Allogeneic mesenchymal stem cell (MSC) transplantation is limited due to the poor engraftment, mitogenic, and differentiation potential in the harsh wound microenvironment. Thus, to improve the efficacy of cell therapy, the chemokine receptor Cxcr2 was overexpressed in MSCs (MSCCxcr2 ). CXCL2/CXCR2 axis induction led to the enhanced proliferation of MSCs through the activation of STAT3 and ERK1/2 signaling. Transcriptional upregulation of FGFR2IIIb (KGF Receptor) promoter by the activated STAT3 and ERK1/2 suggested trans-differentiation of MSCs into keratinocytes...
April 10, 2024: Cellular and Molecular Life Sciences: CMLS
https://read.qxmd.com/read/38590823/evaluating-the-safety-and-efficacy-of-cryopreserved-ovarian-tissue-transplantation-in-leukemia-patients-with-different-bone-marrow-remission-status-using-xenotransplantation
#35
JOURNAL ARTICLE
Yanqiu Li, Xiangyan Ruan, Muqing Gu, Juan Du, Fengyu Jin, Jiaojiao Cheng, Yanglu Li, Lingling Jiang, Zecheng Wang, Yu Yang, Mingzhen Zhang, Alfred O Mueck
BACKGROUND: Leukemia patients undergoing cryopreserved ovarian tissue transplantation (OTT) may carry a high risk of disease induction. Measurable residual disease (MRD) in bone marrow is linked to an elevated risk of relapse. It is controversial whether leukemia patients must be allowed to achieve measurable residual disease negative (MRD-negative) status instead of measurable residual disease positive (MRD-positive) status before ovarian tissue cryopreservation (OTC). OBJECTIVE: To explore the safety and efficacy of OTT in acute leukemia patients with different MRD status by using xenotransplantation...
2024: Frontiers in Endocrinology
https://read.qxmd.com/read/38585489/prevascularized-spongy-like-hydrogels-maintain-their-angiogenic-potential-after-prolonged-hypothermic-storage
#36
JOURNAL ARTICLE
Sara Freitas-Ribeiro, Helena Moreira, Lucília P da Silva, Jennifer Noro, Belém Sampaio-Marques, Paula Ludovico, Mariana Jarnalo, Ricardo Horta, Alexandra P Marques, Rui L Reis, Rogério P Pirraco
The chronic shortage of organs and tissues for transplantation represents a dramatic burden on healthcare systems worldwide. Tissue engineering offers a potential solution to address these shortages, but several challenges remain, with prevascularization being a critical factor for in vivo survival and integration of tissue engineering products. Concurrently, a different challenge hindering the clinical implementation of such products, regards their efficient preservation from the fabrication site to the bedside...
July 2024: Bioactive Materials
https://read.qxmd.com/read/38583875/microwave-hyperthermia-enhances-radiosensitization-by-decreasing-dna-repair-efficiency-and-inducing-oxidative-stress-in-pc3-prostatic-adenocarcinoma-cells
#37
JOURNAL ARTICLE
Yajun Wu, Pengyuan Liu, Wendy Chen, Shiting Bai, Sisi Chen, Jianglin Chen, Xiaogang Xu, Jindan Xia, Yufei Wu, Jianjun Lai, Chuan Sun, Zhenghong Lao, Xiaoqing Wan, Zhibing Wu
PURPOSE: Radiotherapy (RT) is the primary treatment for prostate cancer (PCa); however, the emergence of castration-resistant prostate cancer (CRPC) often leads to treatment failure and cancer-related deaths. In this study, we aimed to explore the use of microwave hyperthermia (MW-HT) to sensitize PCa to RT and investigate the underlying molecular mechanisms. METHODS: We developed a dedicated MW-HT heating setup, created an in vitro and in vivo MW-HT + RT treatment model for CRPC...
2024: International Journal of Hyperthermia
https://read.qxmd.com/read/38583455/remission-induction-versus-immediate-allogeneic-haematopoietic-stem-cell-transplantation-for-patients-with-relapsed-or-poor-responsive-acute-myeloid-leukaemia-asap-a-randomised-open-label-phase-3-non-inferiority-trial
#38
JOURNAL ARTICLE
Matthias Stelljes, Jan Moritz Middeke, Gesine Bug, Eva-Maria Wagner-Drouet, Lutz P Müller, Christoph Schmid, Stefan W Krause, Wolfgang Bethge, Edgar Jost, Uwe Platzbecker, Stefan A Klein, Jörg Schubert, Judith Niederland, Martin Kaufmann, Kerstin Schäfer-Eckart, Markus Schaich, Henning Baldauf, Friedrich Stölzel, Cathleen Petzold, Christoph Röllig, Nael Alakel, Björn Steffen, Beate Hauptrock, Christoph Schliemann, Katja Sockel, Fabian Lang, Oliver Kriege, Judith Schaffrath, Christian Reicherts, Wolfgang E Berdel, Hubert Serve, Gerhard Ehninger, Alexander H Schmidt, Martin Bornhäuser, Jan-Henrik Mikesch, Johannes Schetelig
BACKGROUND: Whether high-dose cytarabine-based salvage chemotherapy, administered to induce complete remission in patients with poor responsive or relapsed acute myeloid leukaemia scheduled for allogeneic haematopoietic stem-cell transplantation (HSCT) after intensive conditioning confers a survival advantage, is unclear. METHODS: To test salvage chemotherapy before allogeneic HSCT, patients aged between 18 and 75 years with non-favourable-risk acute myeloid leukaemia not in complete remission after first induction or untreated first relapse were randomly assigned 1:1 to remission induction with high-dose cytarabine (3 g/m2 intravenously, 1 g/m2 intravenously for patients >60 years or with a substantial comorbidity) twice daily on days 1-3 plus mitoxantrone (10 mg/m2 intravenously) on days 3-5 or immediate allogeneic HSCT for the disease control group...
April 4, 2024: Lancet Haematology
https://read.qxmd.com/read/38583428/high-dose-chemotherapy-and-autologous-stem-cell-transplantation-for-salvage-therapy-of-relapsed-refractory-germ-cell-tumors-a-single-center-experience
#39
JOURNAL ARTICLE
Gul Sema Yıldıran Keskin, Ismail Ertürk, Musa Baris Aykan, Ramazan Acar, Aysegul Dumludag, Alper Topal, Caglar Koseoglu, Omer Faruk Kuzu, Ece Ornek, Nuri Karadurmus
PURPOSE: The optimal management of relapsed/refractory germ cell tumors remains unsettled. In this study, we aimed to evaluate the efficacy of high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) as salvage therapy in patients who progressed after at least one line of cisplatin-based chemotherapy. METHODS: We retrospectively reported the results of 133 patients who underwent HDCT and ASCT as salvage therapy from 2016 to 2021. Patients received 3 cycles of paclitaxel, ifosfomide and cisplatin (TIP) regimen as induction and 1 cycle of carboplatin 700 mg/m2 on days 1 to 3 plus etoposide 750 mg/m2 on days 1 to 3, followed by ASCT...
April 5, 2024: Oncology Research and Treatment
https://read.qxmd.com/read/38581718/clinical-outcomes-of-etoposide-and-cytarabine-as-consolidation-in-elderly-patients-with-primary-cns-lymphoma
#40
JOURNAL ARTICLE
Yu Ri Kim, Hyunsoo Cho, Soo-Jeong Kim, Haerim Chung, Hye Won Kook, Ji Eun Jang, June-Won Cheong, Jin Seok Kim
BACKGROUND: A consolidation strategy has not been established for transplant-ineligible elderly patients with primary central nervous system lymphoma (PCNSL). In this study, we aimed to retrospectively evaluate the clinical outcomes of etoposide and cytarabine (EA) as consolidation chemotherapy for transplant-ineligible patients with PCNSL following high-dose methotrexate (MTX)-based induction chemotherapy. MATERIALS AND METHODS: Between 2015 and 2021, newly diagnosed transplant-ineligible patients with PCNSL with diffuse large B-cell lymphoma were consecutively enrolled...
April 6, 2024: Oncologist
keyword
keyword
75944
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.